25Jul

EKF POC HbA1c analyzer demonstrates excellent performance in international evaluation study

EKF_1

Cardiff, UK – 19 July 2018 – EKF Diagnostics, the global in vitro diagnostics company, has announced the successful evaluation of its Quo-Lab® point-of-care HbA1c analyzer by the European Reference Laboratory for Glycohemoglobin. In a recently published paper [1], the reference laboratory’s evaluation study assessed HbA1c (glycated hemoglobin) POC devices using international quality targets, posing the question ‘Are they fit for purpose?’ Out of 30 available on the market and the four that agreed to participate, only EKF’s Quo-Lab and one other analyzer passed the same stringent quality criteria as laboratory analyzers, achieving excellent analytical performance.

The study aimed to evaluate the four POC HbA1c instruments according to Clinical and Laboratory Standards Institute (CLSI) protocols and how they performed when different criteria were applied using four certified IFCC and NGSP secondary reference measurement procedures (SRMPs). The reference laboratory study confirmed there was minimal bias between Quo-Lab and the mean of four SRMPs, it also passed all relevant performance criteria going far beyond what is required for NGSP and IFCC certification.

Notably, Quo-Lab showed no consistent clinically significant interference from the common hemoglobin (Hb) variants HbAS, HbAC, HbAD, HBAE and elevated A2. It also easily met imprecision criteria, achieving a ≤2.4% CV in IFCC SI units and ≤1.7% CV in DCCT units which represents a significant improvement on previous studies.

This evaluation success follows last year’s similarly excellent evaluation of EKF’s Quo-Test® HbA1c analyzer which was again confirmed to meet IFCC performance criteria [2]. Although not included in this latest study, Lenters-Westra felt it important enough to mention in the conclusion that the Quo-Test’s improved performance also had no bias compared to the mean of three SRMPs [1].

Commenting on the successful European Reference Laboratory for Glycohemoglobin evaluation, Gavin Jones, Diabetes Product Manager, EKF Diagnostics said, “The excellent performance that Quo-Lab has demonstrated in this latest study confirms that it is very definitely fit for purpose, delivering reliable HbA1c results in a range of settings. This study also highlights the performance improvements that we have made to both our Quo-Lab and Quo-Test HbA1c analyzers to fulfill increasingly tough requirements from the IFCC. This means that both analyzers meet the same rigorous quality criteria as laboratory analyzers.”

Quo-Lab® HbA1c is a desktop analyzer designed specifically to meet the needs of diabetes clinics and laboratories in settings that demand low cost of operation and ease of use. From a simple semi-automated procedure, Quo-Lab provides test results within four minutes from a venous or finger prick blood sample of just 4 μL. Quo-Lab uses the same boronate affinity methodology as Quo-Test which is also unaffected by Hb variants. Step-by-step instructions are displayed on a clear, multi-lingual display, therefore, staff training time is minimized and opportunity for error reduced. Quo-Lab is CE marked and available for sale in most global markets subject to local registration requirements.

For full information on the EKF Diagnostics Group, please visit www.ekfdiagnostics.com

References:

  1. Lenters-Westra, E. & English, E. Evaluation of four HbA1c point-of-care devices using international quality targets: Are they fit for purpose? J Diabetes Sci Technol. 2018 Jul;12(4):762-770. 
  2. Lenters-Westra, E. & English, E. Understanding the use of sigma metrics in hemoglobin A1c analysis. Clin Lab Med 2017;37: 57-71.

Related

Entrust People and SCI Search & Selection rebrand to Entrust Resource Solutions

Following a year of strong growth and successful acquisitions, Entrust People and SCI Search & Selec...

Read More >

European Reference Laboratory for Glycohemoglobin study reaffirms EKF’s Quo-Test® meets HbA1c performance criteria

Cardiff, UK – 16th February 2017 – EKF Diagnostics, the global in vitro diagnostics company, annou...

Read More >

IPP signs a significant deal with BBI Solutions on Ginolis LFDA assembly line delivery

Industrial Production Processes (IPP) Ltd today announced that it has signed a contract with BBI Sol...

Read More >

Biofortuna closes £1.6M funding round

Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract m...

Read More >

OGT unveils reliable somatic CNV detection for CLL with new NGS panel

SureSeq™ CLL + CNV - comprehensive CLL genomic profiling from a single assay

Read More >

EKF launches pocket-sized lactate monitor for sports performance monitoring at MEDICA 2018

Cardiff, UK – 22nd October 2018 – EKF Diagnostics, the global in vitro diagnostics company, announ...

Read More >